Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Five3 Genomics LLC is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Despite having multiple actions, the company interacts with only 1 distinct examiner and 1 distinct art unit. This suggests that while the volume of activity is 2 pending office actions, the technical and personnel focus remains concentrated. This concentration can lead to a predictable prosecution experience if the relationship with the examiner is positive.
ZEMAN, MARY K is the busiest examiner for the portfolio, with 2 busiest examiner pending actions currently assigned. This matches the 2 pending office actions for the company, meaning this examiner is responsible for every active action in the portfolio. This concentration gives the examiner influence over the company's intellectual property assets, as their decisions affect all currently pending matters.
For practitioners, the use of 1 distinct art unit for these actions indicates a consistent application of technical standards across the portfolio. The current volume of office actions suggests a period of negotiation or review. All current prosecution outcomes are linked to the specific interpretations of ZEMAN, MARY K, making it essential to understand this examiner's historical patterns and preferences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, MARY K | 2 | 59.0% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17739792 | Systems, Methods, and Compositions for Viral-Associated Tumors | ZEMAN, MARY K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16222798 | Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations | ZEMAN, MARY K | 77d overdue |
| 17739792 | Systems, Methods, and Compositions for Viral-Associated Tumors | ZEMAN, MARY K | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17739792 | Systems, Methods, and Compositions for Viral-Associated Tumors | ZEMAN, MARY K | 1686 | §101§102Other | Non-Final OA | — | Pending | May 09, 2022 |
| 16222798 | Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations | ZEMAN, MARY K | 1686 | §112Other | Non-Final OA | 77d overdue | Pending | Dec 17, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial